PwC provided advisory on the acquisition of a pharmaceutical business of Kolmar Korea Co., Ltd. for IMM Private Equity

The PwC Korea deal team is pleased to announce that it has advised IMM PE("IMM") on its acquisition of a pharmaceutical business of Kolmar Korea co., ltd ("Kolmar"). The deal was closed on December 28, 2020 and PwC also provided due diligence on settlement and PMI to IMM in connection with the deal. Final price settlement was completed in early April 2021.

PwC Korea teams offered deep expertise in the bio/health industry transaction experience with insights and collaborated to help securing a positive outcome by providing financial due diligence and tax structuring advice to IMM, one of Korea's top performing and largest Private Equity. 

PwC Korea contributed to increase the deal value by considering the synergy effect between Kolmar's pharmaceutical division and its subsidiary (Kolmar Pharma) in the proposed transaction structure and supported and collaborated with PwC Panacea where the PwC Panacea team contributed in negoitating and closing the price gap between buyers and sellers to successfully close the deal. This transaction demonstrates an ideal example of VCiD (Value Creation in Deals) in M&A, PwC's strategic focused area of services where PwC's community of specialists can combine in-depth experience in deliverying the deal over the deal life cycle from the deal origination, pre-deal services in pharmaceutical and health sector specific PMI/Bolt-on M&A to post-deal services.

The PwC team advising on the deal was led by Doshin Lee and Hong-Seo Yu.